Compare OTIS & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OTIS | RVMD |
|---|---|---|
| Founded | 1853 | 2014 |
| Country | United States | United States |
| Employees | N/A | 883 |
| Industry | Consumer Electronics/Appliances | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.7B | 30.1B |
| IPO Year | 2019 | N/A |
| Metric | OTIS | RVMD |
|---|---|---|
| Price | $73.38 | $182.06 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 19 |
| Target Price | $99.63 | ★ $140.84 |
| AVG Volume (30 Days) | ★ 3.4M | 3.0M |
| Earning Date | 04-22-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.30% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.87 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.94 | N/A |
| Revenue Next Year | $4.83 | $533.02 |
| P/E Ratio | $84.56 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $69.16 | $34.00 |
| 52 Week High | $101.42 | $184.39 |
| Indicator | OTIS | RVMD |
|---|---|---|
| Relative Strength Index (RSI) | 53.01 | 72.39 |
| Support Level | $69.39 | $93.39 |
| Resistance Level | $92.15 | N/A |
| Average True Range (ATR) | 1.58 | 6.74 |
| MACD | 0.46 | 2.09 |
| Stochastic Oscillator | 63.52 | 88.54 |
Otis is the largest global elevator and escalator supplier by revenue with around 18% global market share. In 1854 Otis' founder and namesake Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed. The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15- to 20-year useful life of an elevator. As the largest global OEM, Otis has amassed an installed base under service that exceeds 2 million elevators. Its business model is similar to that of its closest competitors Kone, Schindler, and TK Elevator.
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.